Typhoid vaccine (inactivated)
Brand names: Typhim Vi, Typherix
An inactivated vaccine (Vi capsular polysaccharide injection) used to provide active immunisation against Salmonella Typhi for travellers to endemic areas and certain occupational groups.
Adult dose
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance, to any of the excipients, or to any residual substances that may be present as traces such as formaldehyde or casein (§4.3)
- Vaccination must be postponed in case of febrile or acute disease (§4.3)
Side effects
- Very common: injection site pain (75.6% in adults, 52.6% in children and adolescents); myalgia (very common in both adults and children/adolescents, 14.6% in children and adolescents)
- Very common in children and adolescents 2-17 years, common in adults: headache (13.5% in children and adolescents); injection site erythema (14.4% in children and adolescents)
- Very common in children and adolescents, common in adults: injection site swelling/oedema/induration (16.5% in children and adolescents)
- Very common in adults, common in children and adolescents: malaise and fatigue/asthenia. Fever was common in children and adolescents. Injection site pruritus was uncommon in adults
- Frequency not known (post-marketing surveillance): anaphylactic and anaphylactoid reactions including shock; serum sickness disease; vasovagal syncope in response to injection; asthma; nausea, vomiting, diarrhoea, abdominal pain; allergic type reactions such as pruritus, rash and urticaria; arthralgia. Most adverse reactions appeared within 3 days after vaccination and most resolved spontaneously within 1 to 3 days after onset
Interactions
- Separate injection sites must be used in case of concomitant vaccine administration (§4.5)
- TYPHIM Vi may be administered during the same vaccination session with other common vaccines: yellow fever, diphtheria, tetanus, poliomyelitis, rabies prepared on Vero cells, meningitis A+C, hepatitis A and hepatitis B (§4.5)
- Immunosuppressive treatment or immunodeficiency may reduce the immunogenicity of the vaccine; it is recommended to postpone vaccination until the end of the disease or treatment (§4.4)
Clinical monograph
How it works
The purified Vi capsular polysaccharide antigen stimulates a T-cell-independent humoral antibody response against the typhoid bacterium, conferring partial protection.
Prescribing in practice
- Protection is incomplete, so vaccinees must still be counselled on food, water and personal hygiene precautions; booster doses are needed for continued exposure.
- Administer well in advance of travel to allow time for the immune response to develop.
- It does not protect against paratyphoid fever or other gastrointestinal pathogens.
Monitoring
No routine laboratory monitoring is required; observe briefly after injection for immediate hypersensitivity reactions.
Counselling the patient
- Keep maintaining strict food and water hygiene as the vaccine does not give complete protection.
- A repeat dose is required before further travel if exposure continues.
- Mild soreness at the injection site, headache or low-grade fever may occur.
Evidence & guidelines
Use is guided by UK national immunisation guidance (the Green Book) and current travel-health recommendations.
Reference: UKHSA Green Book Ch.33; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023